UA74991C2 - Oral therapeutic composition with controlled release of dihydrocodeine - Google Patents
Oral therapeutic composition with controlled release of dihydrocodeine Download PDFInfo
- Publication number
- UA74991C2 UA74991C2 UA20041109250A UA20041109250A UA74991C2 UA 74991 C2 UA74991 C2 UA 74991C2 UA 20041109250 A UA20041109250 A UA 20041109250A UA 20041109250 A UA20041109250 A UA 20041109250A UA 74991 C2 UA74991 C2 UA 74991C2
- Authority
- UA
- Ukraine
- Prior art keywords
- weight
- active substance
- mixture
- composition according
- dihydrocodeine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 13
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 title claims abstract description 11
- 229960000920 dihydrocodeine Drugs 0.000 title claims abstract description 10
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 title claims abstract description 10
- 238000013270 controlled release Methods 0.000 title claims abstract description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 33
- 239000013543 active substance Substances 0.000 claims abstract description 22
- UKMSUNONTOPOIO-UHFFFAOYSA-N docosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCCCCC(O)=O UKMSUNONTOPOIO-UHFFFAOYSA-N 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 18
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000021357 Behenic acid Nutrition 0.000 claims abstract description 10
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 10
- 229940116226 behenic acid Drugs 0.000 claims abstract description 10
- XAAHAAMILDNBPS-UHFFFAOYSA-L calcium hydrogenphosphate dihydrate Chemical compound O.O.[Ca+2].OP([O-])([O-])=O XAAHAAMILDNBPS-UHFFFAOYSA-L 0.000 claims abstract description 10
- 229920001577 copolymer Polymers 0.000 claims abstract description 9
- 150000002148 esters Chemical class 0.000 claims abstract description 9
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 239000001530 fumaric acid Substances 0.000 claims abstract description 5
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims abstract description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 5
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 4
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 159000000000 sodium salts Chemical class 0.000 claims abstract description 4
- 239000002245 particle Substances 0.000 claims description 12
- 239000000126 substance Substances 0.000 claims description 9
- -1 alkali metal salt Chemical class 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052783 alkali metal Inorganic materials 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 230000000202 analgesic effect Effects 0.000 claims description 2
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims 1
- 101100287724 Caenorhabditis elegans shk-1 gene Proteins 0.000 claims 1
- 239000001506 calcium phosphate Substances 0.000 claims 1
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 1
- 235000011010 calcium phosphates Nutrition 0.000 claims 1
- 150000004683 dihydrates Chemical class 0.000 claims 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 5
- 238000009472 formulation Methods 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 229940117958 vinyl acetate Drugs 0.000 abstract 1
- 235000011187 glycerol Nutrition 0.000 description 9
- ZGSZBVAEVPSPFM-HYTSPMEMSA-N (4r,4ar,7s,7ar,12bs)-9-methoxy-3-methyl-2,4,4a,5,6,7,7a,13-octahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-7-ol;(2r,3r)-2,3-dihydroxybutanedioic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC ZGSZBVAEVPSPFM-HYTSPMEMSA-N 0.000 description 8
- 238000003825 pressing Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- 238000000227 grinding Methods 0.000 description 5
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 4
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 229940082500 cetostearyl alcohol Drugs 0.000 description 4
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 4
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000005469 granulation Methods 0.000 description 3
- 230000003179 granulation Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 239000007916 tablet composition Substances 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 229960001375 lactose Drugs 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000003763 resistance to breakage Effects 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 206010072005 Spinal pain Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000005243 fluidization Methods 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- RBNPOMFGQQGHHO-UHFFFAOYSA-N glyceric acid Chemical compound OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000009475 tablet pressing Methods 0.000 description 1
- 229940033134 talc Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SK501-2002A SK286107B6 (sk) | 2002-04-12 | 2002-04-12 | Analgeticky účinný perorálny liečivý prípravok s kontrolovaným uvoľňovaním opioidnej účinnej látky a spôsob jeho prípravy |
| PCT/SK2003/000008 WO2003086365A1 (en) | 2002-04-12 | 2003-04-10 | Analgesical oral composition with controlled release of an opioid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA74991C2 true UA74991C2 (en) | 2006-02-15 |
Family
ID=29247067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA20041109250A UA74991C2 (en) | 2002-04-12 | 2003-10-04 | Oral therapeutic composition with controlled release of dihydrocodeine |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1494656B1 (cs) |
| AT (1) | ATE398446T1 (cs) |
| AU (1) | AU2003219641A1 (cs) |
| CZ (1) | CZ20041054A3 (cs) |
| DE (1) | DE60321672D1 (cs) |
| EA (1) | EA006846B1 (cs) |
| GE (1) | GEP20063991B (cs) |
| HU (1) | HUP0500438A3 (cs) |
| NO (1) | NO20044502L (cs) |
| PL (1) | PL372698A1 (cs) |
| SK (1) | SK286107B6 (cs) |
| UA (1) | UA74991C2 (cs) |
| WO (1) | WO2003086365A1 (cs) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2058111T3 (es) * | 1986-06-10 | 1994-11-01 | Euro Celtique Sa | Composicion de liberacion controlada de dihidrocodeina. |
| FR2753904B1 (fr) * | 1996-10-01 | 1998-10-30 | Gattefosse Ets Sa | Composition pharmaceutique a liberation modifiee de principe actif, comportant une matrice, et procede de fabrication |
| DE19747261A1 (de) * | 1997-10-25 | 1999-04-29 | Bayer Ag | Osmotisches Arzneimittelfreisetzungssystem |
| EP2269587A1 (en) * | 1999-10-29 | 2011-01-05 | Euro-Celtique S.A. | Controlled release hydrocodone formulations |
| SK285128B6 (sk) * | 1999-12-28 | 2006-07-07 | Zentiva, A. S. | Liečivý prípravok s riadeným uvoľňovaním obsahujúci tramadol hydrochlorid a spôsob jeho prípravy |
-
2002
- 2002-04-12 SK SK501-2002A patent/SK286107B6/sk not_active IP Right Cessation
-
2003
- 2003-04-10 HU HU0500438A patent/HUP0500438A3/hu unknown
- 2003-04-10 GE GEAP8496A patent/GEP20063991B/en unknown
- 2003-04-10 PL PL03372698A patent/PL372698A1/xx not_active Application Discontinuation
- 2003-04-10 WO PCT/SK2003/000008 patent/WO2003086365A1/en not_active Ceased
- 2003-04-10 DE DE60321672T patent/DE60321672D1/de not_active Expired - Fee Related
- 2003-04-10 AT AT03715908T patent/ATE398446T1/de not_active IP Right Cessation
- 2003-04-10 EA EA200401357A patent/EA006846B1/ru not_active IP Right Cessation
- 2003-04-10 AU AU2003219641A patent/AU2003219641A1/en not_active Abandoned
- 2003-04-10 EP EP03715908A patent/EP1494656B1/en not_active Expired - Lifetime
- 2003-04-10 CZ CZ20041054A patent/CZ20041054A3/cs unknown
- 2003-10-04 UA UA20041109250A patent/UA74991C2/uk unknown
-
2004
- 2004-10-21 NO NO20044502A patent/NO20044502L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1494656A1 (en) | 2005-01-12 |
| WO2003086365A1 (en) | 2003-10-23 |
| AU2003219641A1 (en) | 2003-10-27 |
| NO20044502L (no) | 2004-10-26 |
| HUP0500438A2 (hu) | 2005-08-29 |
| PL372698A1 (en) | 2005-07-25 |
| CZ20041054A3 (cs) | 2005-01-12 |
| ATE398446T1 (de) | 2008-07-15 |
| DE60321672D1 (de) | 2008-07-31 |
| GEP20063991B (en) | 2006-12-11 |
| SK5012002A3 (en) | 2003-11-04 |
| EP1494656B1 (en) | 2008-06-18 |
| SK286107B6 (sk) | 2008-03-05 |
| HUP0500438A3 (en) | 2008-03-28 |
| EA006846B1 (ru) | 2006-04-28 |
| EA200401357A1 (ru) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100402585C (zh) | 多孔纤维素聚集体以及包含这种聚集体的组合物成形品 | |
| TW200529803A (en) | Extrusion process for forming chemically stable drug multiparticulates | |
| RU2208436C2 (ru) | Способ изготовления фармацевтических лекарственных форм и их предшественников и фармацевтическая лекарственная форма | |
| WO1995005809A1 (en) | Gastric remaining preparation, swollen molding, and production process | |
| CZ303694B6 (cs) | Prípravek nesteroidního protizánetlivého léciva obsahující granulární a extragranulární kompozici a zpusob jeho prípravy | |
| CA2397942C (en) | Controlled release pharmaceutical composition containing tramadol hydrochloride and method for its preparation | |
| JP5663238B2 (ja) | 内服固形製剤及びその製造方法 | |
| CN112603900A (zh) | 含[(4-羟基-1-甲基-7-苯氧基-异喹啉-3-羰基)-氨基]-乙酸的固体制剂 | |
| JP2011246428A (ja) | 口腔内崩壊型医薬品及びその製造方法 | |
| RU2414888C1 (ru) | Таблетка из активной фармацевтической субстанции (варианты) и способ ее получения | |
| UA74991C2 (en) | Oral therapeutic composition with controlled release of dihydrocodeine | |
| EP4056638A1 (en) | Cellulose composition, tablet, and orally disintegrating tablet | |
| EP3256105B1 (en) | Method of producing a granulated composition | |
| JP2022076474A (ja) | リバーロキサバン含有口腔内崩壊錠 | |
| JP2005255619A (ja) | 昇華性活性成分および多孔質セルロース粒子含有固形製剤組成物 | |
| CN112336691A (zh) | 一种利托那韦片及其制备方法 | |
| JP2007332074A (ja) | 口腔内速崩壊錠およびその製造方法 | |
| CN114983954A (zh) | 叶酸片及其制备方法 | |
| JP5817715B2 (ja) | 固形医薬組成物、医薬製剤及び固形医薬組成物の製造方法 | |
| CN118340731A (zh) | 一种硫酸瑞美吉泮药物组合物及其制备方法 | |
| TR2022018634A2 (tr) | Geli̇şti̇ri̇lmi̇ş prasugrel hi̇droklorür fi̇lm kapli tablet formülasyonlari i̇çi̇n üreti̇m yöntemi̇ | |
| JP2008214325A (ja) | 固形製剤 | |
| CZ20131028A3 (cs) | Kombinovaný perorální přípravek s řízeným uvolňováním kyseliny acetylsalicylové a způsob přípravy | |
| SK6002Y1 (sk) | Combined peroral controlled-release formulation of acetylsalicylic acid | |
| HU191102B (en) | Process for producing pharmaceutical compositions of regulated dissolution of the active agents containing water-soluble inorganic pharmacons |